=
A produtividade de P&D está diminuindo há décadas, mas um recorde de 53 novos medicamentos terapêuticos aprovados pelo FDA dos EUA em 2014 sugerem que as fortunas da indústria de biopharma mudaram.
Educação
- PhD, Instituto Federal Swiss de Tecnologia (ETH), Zurique
- LLB, honors, Australian National University
- BSc , honors, , Australian National University
Honors and Awards
- University Medal, Australian National University
David is the leader of Boston Consulting Group's Health Care practice in Switzerland and has worked extensively with clients in the pharmaceutical and biotech industries in Europe, the US, and emerging markets.
David collaborates with clients on a broad range of strategic and operational topics including commercial, market access, medical affairs, R&D, corporate strategy, and large-scale Transformações.
Prior to joining our Zurich office, David conducted doctoral research in molecular biotechnology, focusing on gene control and delivery applications for recombinant protein production and therapeutic use.
